UCB’s Kola joins Astex board

pharmafile | June 5, 2010 | Appointment | Research and Development Astex, UCB, appointment, research and development 

Dr Ismail Kola has joined the board of directors at UK biotech company Astex Therapeutics.

Astex’s non-executive chairman Peter Fellner said: “I am delighted that Ismail has decided to join Astex’s Board at this time in the company’s development. With three of our products about to enter into phase II clinical trials, Ismail’s exceptionally broad experience in pharmaceutical research and development will be an enormous asset to Astex as we continue to capture the value of the company’s technology and products going forward.”

Dr Kola is currently president of new medicines at UCB, having joined the Belgium pharma company from Schering-Plough in November 1999.

At Schering-Plough he served as senior VP of discovery research and early clinical research and experimental medicine and prior to this held senior positions at Merck and Pharmacia (now part of Pfizer).

Related Content

FDA accepts UCB’s sBLA for Bimzelx

UCB has announced that the US Food and Drug Administration (FDA) has accepted for review …

Microsoft and UCB collaborate to treat immunological and neurological diseases

UCB and Microsoft have agreed a new multi-year collaboration to discover new medicines by combining …

shutter

UCB syncs up with Roche and Genentech in Alzheimer’s drug deal worth a potential $2bn+

UCB Pharma is set to partner up with Roche and Genentech in a development and …

Latest content